As the beginning of a new genetic age in cancer research mounts, three pharmaceutical companies are poised to test whether new drugs can work against a wide range of cancers independently of where they originated.
Such drugs could mean new treatments for rare, neglected cancers, as well as common ones affecting the breast, prostate, liver and lung. The drugs go after an aberration involving a cancer gene fundamental to tumor growth.
Merck, Roche and Sanofi are racing to develop their own versions of a drug they hope will restore a mechanism that normally makes badly damaged cells self-destruct and could potentially be used against half of all cancers.
"This is a taste of the future in cancer drug development," said Dr. Otis Webb Brawley, the chief medical and scientific officer of the American Cancer Society. "I expect the organ from which the cancer came from will be less important in the future and the molecular target more important." Read the full details here:
Drugs Aim to Make Several Types of Cancer Self-Destruct
Until the cure for cancer is found, the disease will continue to claim the lives of millions. Unfortunately, many die due to the failure to diagnose cancer when it should have been found earlier on radiology studies or lab studies ignored by physicians.
If you or a family member have a malpractice case due to the failure to diagnose cancer, contact Crandall & Pera Law today for a free case evaluation.